SELLAS Life Sciences Group, Inc. (SLS) Reports Preclinical SLS009 Activity in PDAC Models

SELLAS reported preclinical data showing SLS009 (CDK9 inhibitor) activity in MYC—amplified pancreatic cancer organoid models, including a daraxonrasib—resistant model, and synergy with BET inhibitor ZEN3694.Material DetailsContext by AI AnalystThis is early, preclinical evidence expanding SLS009’s…